What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Breast cancer
David A. Mankoff mostly deals with Breast cancer, Nuclear medicine, Positron emission tomography, Internal medicine and Radiology.
David A. Mankoff interconnects Locally advanced, Chemotherapy and Pathology in the investigation of issues within Breast cancer.
His study on Standardized uptake value and Fluorodeoxyglucose is often connected to Kinetic analysis and Thymidine kinase 1 as part of broader study in Nuclear medicine.
The study incorporates disciplines such as Cancer, Mediastinum, Lymph node, Bone scintigraphy and Primary tumor in addition to Positron emission tomography.
The Internal medicine study combines topics in areas such as Surgery, Oncology and Systems biology.
His Radiology study integrates concerns from other disciplines, such as Appropriate Use Criteria, Retrospective cohort study, Breast carcinoma, Breast cancer screening and Breast ultrasound.
His most cited work include:
- Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials (597 citations)
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development (505 citations)
- Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. (348 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Breast cancer, Internal medicine, Nuclear medicine, Positron emission tomography and Oncology.
His Breast cancer study incorporates themes from Radiology, Chemotherapy and Pathology.
The concepts of his Nuclear medicine study are interwoven with issues in Locally advanced, Prospective cohort study and Progression-free survival.
His Positron emission tomography research focuses on Molecular imaging and how it connects with Medical physics and Cancer therapy.
His research integrates issues of Biomarker, Primary tumor and Disease in his study of Oncology.
His Cancer research integrates issues from Cancer research and Clinical trial.
He most often published in these fields:
- Breast cancer (39.82%)
- Internal medicine (30.89%)
- Nuclear medicine (28.83%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (30.89%)
- Oncology (27.46%)
- Cancer (21.74%)
In recent papers he was focusing on the following fields of study:
David A. Mankoff focuses on Internal medicine, Oncology, Cancer, Breast cancer and Positron emission tomography.
His Oncology study also includes fields such as
- Clinical trial and related Medical physics,
- Radiation therapy together with External beam radiotherapy and Lung cancer.
He combines subjects such as Immunohistochemistry, Ex vivo and Cancer research with his study of Cancer.
His study in Breast cancer is interdisciplinary in nature, drawing from both Fluorodeoxyglucose, Radiology, Nuclear medicine and Disease.
David A. Mankoff usually deals with Nuclear medicine and limits it to topics linked to Progression-free survival and Progressive disease.
The study incorporates disciplines such as Molecular imaging, Magnetic resonance imaging, Prostate cancer and Iterative reconstruction in addition to Positron emission tomography.
Between 2016 and 2021, his most popular works were:
- Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology (127 citations)
- Future cancer research priorities in the USA: a Lancet Oncology Commission (78 citations)
- The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. (54 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
David A. Mankoff mainly focuses on Cancer, Internal medicine, Oncology, Breast cancer and Positron emission tomography.
His studies in Cancer integrate themes in fields like Ex vivo, Cancer research, Antibiotics, Biodistribution and MEDLINE.
His study in the field of Ischemia, Myocardial infarction, Stroke and Blood flow also crosses realms of Fractional flow reserve.
His Oncology research includes themes of Magnetic resonance imaging, Clinical trial and Ovarian cancer.
His biological study spans a wide range of topics, including Clinical endpoint, Radiology and Nuclear medicine.
His Positron emission tomography research is multidisciplinary, incorporating perspectives in Molecular imaging, Computational physics and Estimation theory.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
